Abstract:Lupus nephritis always elicits immune inflammatory tissue damages in kidney. Pentraxin 3 (PTX3), mainly produced at inflammatory sites, is known to be involved in the regulation of the innate immunity system. The aim of this study was to investigate the serum and urine levels of PTX3, and the expression of PTX3 in renal tissues in lupus nephritis patients from a large Chinese cohort.The study used cross-sectional survey and 288 active lupus nephritis patients, including discovery cohort and validation cohort, 115 systemic lupus erythematosus (SLE) patients without clinical renal involvement and 46 healthy controls were enrolled. Serum and urine PTX3 were screened by enzyme-linked immunosorbent assay (ELISA). The renal deposition of PTX3 was detected by immunohistochemistry and immunofluorescence.The average level of serum PTX3 in the discovery cohort of lupus nephritis was significantly higher than that in nonrenal involvement SLE group and normal controls (P < 0.001, P < 0.001, respectively), which was confirmed by the validation cohort. Serum PTX3 levels of 15 lupus nephritis patients in remission decreased significantly compared with that in active phase. Serum PTX3 levels were significantly higher in patients with hematuria (P = 0.014), leucocyturia (P = 0.002), acute renal failure (P = 0.001), and nephrotic syndrome (P = 0.036). There were significant correlations between serum PTX3 levels and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores, serum creatinine value, renal pathological activity indices, and serum complement 3 (C3) in active lupus nephritis patients. The urinary PTX3 levels were significantly higher in active lupus nephritis patients compared with patients in remission and normal controls (P = 0.011, P = 0.008, respectively). There were significant associations between urinary PTX3 levels and multiple indices of tubulointerstitial lesions, including urinary KIM-1 (r = 0.368, P = 0.016), neutrophil gelatinase-associated lipocalin (NGAL) (r = 0.320, P = 0.039), microalbumin (r = 0.621, P = 0.003), transferring (r = 0.451, P = 0.040) levels and renal pathological indices scores, especially interstitial inflammation (r = 0.349, P = 0.025) in active lupus nephritis patients. A significant correlation was found between serum and urine PTX3 levels (r = 0.431, P = 0.006). PTX3 staining was mainly observed in tubulointerstitial areas of patients with lupus nephritis, and immunofluorescence study showed that PTX3 could colocalize with fibroblast in interstitium.Circulating and local PTX3 levels were significantly increased in patients with active lupus nephritis and might be a biomarker for the disease progression, especially of tubulointerstitial injury.

Pentraxin 3: A promising therapeutic target for autoimmune diseases

Molecular insight into pentraxin-3: Update advances in innate immunity, inflammation, tissue remodeling, diseases, and drug role

Pentraxin 3: A promising Therapeutic Target for Cardiovascular Diseases

The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling

The inflammatory protein Pentraxin 3 in cardiovascular disease

Pentraxins in Humoral Innate Immunity

Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications

P2X7 receptor: A potential therapeutic target for autoimmune diseases

Pentraxin 3 is Closely Associated with Tubulointerstitial Injury in Lupus Nephritis

Increased Circulating Pentraxin 3 Levels in Patients with Rheumatoid Arthritis: A Meta-analysis

Post-translational Modifications in T Cells in Systemic Erythematosus Lupus

Pentraxin 3 Is Closely Associated With Tubulointerstitial Injury in Lupus Nephritis: A Large Multicenter Cross-Sectional Study.

NLRP3: A promising therapeutic target for autoimmune diseases

Pentraxin 3 in Myocarditis: Proof-of-Principle Assessment as a Diagnostic and Prognostic Biomarker

Pentraxin 3 exacerbates psoriasiform dermatitis through regulation of macrophage polarization

Pattern Recognition by Pentraxins

Pentraxins in invertebrates and vertebrates: From structure, function and evolution to clinical applications

Pentraxin-3 As a Marker of Advanced Atherosclerosis Results from the Bruneck, ARMY and ARFY Studies

Association between blood Pentraxin‐3 concentrations and rheumatic diseases: A systematic review and meta‐analysis

Pentraxin 3 deficiency ameliorates the severity of osteoarthritis and alleviates inflammation

Progress in the study of pentraxin-3(PTX-3) as a biomarker for sepsis